Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment
Treatment options may include: Semaglutide (Ozempic, Wegovy) Tirzepatide (Mounjaro, Zepbound) Compounded options when clinically appropriate All medications are prescribed based on your medical evaluation and monitored by a licensed provider
Common side effects include more frequent urination, mild dehydration, and a higher chance of urinary tract or yeast infections
Retatrutide is an investigational triple receptor agonist acting on GLP-1, GIP, and glucagon receptors currently available only through authorised clinical trials for obesity and type 2 diabetes
At your initial consultation, well discuss your individual needs and goals to determine the best treatment plan for you, including injection frequency